Drug Trial Radar · NCT03578900
Quality of Life and Sjögren Syndrome
Last checked: Nov 20, 2026Latest source record: Jul 6, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
289
Actual
Start
Jan 1, 2013
Primary completion
Dec 31, 2014
Study completion Dec 31, 2016
Sponsor
- Lead sponsor
- Grupo de Investigação em Bioquímica e Biologia OralAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- University of Lisbon; Portuguese Institute of Rheumatology; Dentaid SL
- First posted
- Jul 6, 2018
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The aims of this study are: To compare salivary pH changes and stimulation efficacy of two different Gustatory Stimulants of Salivation (GSSS) in patients with Primary Sjögren Syndrome (PSS); To evaluate Primary Sjögren syndrome (PSS) impact and gustatory stimulants of salivary secretion (GSSS) on oral health related quality of life measured by a Portuguese version of Oral Health Impact Profile-14 (OHIP-14) and specific Xerostomia assessment questionnaires. The Products to be used are the Xeros® Dentaid system and a citric based mouthwash.
Conditions
- Xerostomia
- Hyposalivation
- Quality of Life
- Sjogren's Syndrome
Interventions
XerosDrug
Citric Acid based MouthwashDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time of GSSS induced pH drop below 4.5Time frame: 20 minutes
- Overall and sub domains scores for each questionnaireTime frame: 15 days
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.